newsfilter
← Latest News
GlobeNewswire·

Reneo Pharmaceuticals Announces Last Patient Last Visit in the Pivotal STRIDE Study of Mavodelpar in Primary Mitochondrial Myopathies (PMM)

IRVINE, Calif., Oct. 09, 2023 (GLOBE NEWSWIRE) -- Reneo Pharmaceuticals, Inc. (NASDAQ:RPHM), a clinical-stage pharmaceutical company focused on the development and commercialization of therapies for patients with rare